China Net Finance, February 5 (Reporter Zhang Zengyan) A few days ago, Aonong Biotechnology announced that the company's controlling shareholder Aonong Investment recently received the "Notice" from the creditor Dazhou Group, because Aonong Investment failed to pay off the due debts on time and obviously lacked solvency, it has submitted materials to the people's court to apply for the reorganization of Aonong Investment. As of the date of the announcement, Aonong Investment has not received the documents from the court to accept the reorganization application.
In this regard, Aonong Biotech said that there is still significant uncertainty as to whether Dazhou Group's application can be accepted by the court and whether Aonong Investment will enter the reorganization procedure, which may have an impact on the company's equity structure.
At present, Aonong Investment holds 26.6 billion shares, accounting for 30 percent of the company's total share capital58%。Among them, the number of pledged shares is 26 billion shares, accounting for 97 of its shares73%；The number of frozen shares is 26.6 billion shares, accounting for 100% of its shares.
In addition to the unoptimistic situation of the controlling shareholder Aonong Investment, Aonong Biotech is also in a debt crisis. As of January 23, the company has accumulated a total of about 143.8 billion yuan. Corporate litigation increased due to the impact of the debt situation. From November 2022 to January 30, 2024, the cumulative litigation (arbitration) amount of Aonong Biotech is 194.9 billion yuan.
In terms of performance, Aonong Biotech expects to continue to lose money in 2023, achieving a net profit attributable to shareholders of listed companies of -3 billion yuan to -3.6 billion yuan; It is estimated that the net assets attributable to shareholders of listed companies by the end of 2023 will be 700 million yuan to -1 billion yuan.
As the net assets at the end of 2023 are expected to be negative, according to relevant regulations, Aonong Biotech has issued a reminder that the company** may be subject to delisting risk warning, and is expected to issue two more risk warning announcements before the disclosure of the 2023 annual report.